Xinju Xiaogao Prescription Study on Overweight
Not Applicable
Completed
- Conditions
- Overweight
- Interventions
- Drug: placebo
- Registration Number
- NCT01142076
- Brief Summary
Xinju Xiaogao prescription and 10% of it in the treatment of adiposity (stagnation of QI causing phlegm retention)clinical study
- Detailed Description
Charged by the three research centers in line with traditional Chinese medicine stagnation of QI causing phlegm retention 120 cases have diabetes were randomly divided into Chinese herbal compound Xinju Xiaogao prescription group and 10% of the prescription group.The treatment groups were compared 24-week step-down and regulation of body weight,waistline, blood lipids, blood sugar effect.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
- Aged 18-60 years old
- BMI≥28kg/m2,but<40kg/m2
- Waistline≥85cm(male),≥80cm(female)
- Pathoglycemia must fulfill one of those four condition:
- IGT,7.8≤2hPG≤11.0mmol/,
- diabetics take medicine used to treat type 2 diabetes more than 3 month,and 5.6≤FBG≤12.2,and weight change under 4kg.
- stagnation of QI causing phlegm retention
- To sign informed consent.
Exclusion Criteria
- After 3-6 months simply controlling their diet and more exercise treatment, body weight weight loss ≥ 5%.
- TG>4.5mmol/L.
- Suffering from congenital heart disease, rheumatic heart disease, kidney disease, serious active liver disease, peptic ulcer disease or malabsorption syndrome.
- There is a history of pancreatitis or endocrine diseases other than diabetes, diabetes treated with insulin.
- Not suffered myocardial infarction in Past 3 months or unstable angina were confirmed.
- Had been diagnosed as "post-surgical adhesions" .
- There is a history of appetite or abuse of laxatives
- Diastolic blood pressure,uncontrolled or controlled, three times greater than 105mmHg .
- Pregnancy, prepare to pregnant or lactating women prepare.
- Allergies to Chinese medicine , allergic.
- Recurrent gallstone or a history of kidney stones.
- Mentally ill.
- Cancer patients.
- A history of gastrointestinal surgery to lose weight.
- Receiving other clinical studies nearly 3 months.
- Alcohol and / or psychoactive substances, drug abusers and addicts.
- Taking other weight-reducing aid Close within one month
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo placebo Dose treatment group, 10% Xinju Xiaogao Prescription Xinju Xiaogao Prescription treatment group
- Primary Outcome Measures
Name Time Method waistline up to 24 weeks
- Secondary Outcome Measures
Name Time Method Body Mass Index (BMI) up to 24 weeks